Connect your AI

CG Oncology CGON Proceeds from disposition of marketable securities and other investments

Proceeds from disposition of marketable securities and other investments at other companies

Johnson & JohnsonJNJ

$209M-4.1%

Vir Biotechnology, Inc.VIR

——

Other financials

Income statement

Revenue$1.1M+1,983%

Operating income-$66.4M-57.3%

Net income-$60.2M-74.7%

EPS (diluted)-$0.71-57.8%

Balance sheet

Cash & equivalents$33.7M-18.7%

Total debt$7.6M+631%

Total equity$1.1B+54.9%

Total assets$1.1B+55.9%

Cash flow

Operating cash flow-$56.9M-94.5%

CapEx$304.0K+1,800%

Free cash flow-$57.2M-95.4%

Valuation

Market cap$5.8B+206%

Profitability

Operating margin-4,239%-1,872pp

Net margin-3,682.6%-1,601pp

FCF margin-3,163.8%-1,351pp

Returns & leverage

Return on equity-20.8%+7.1pp

Debt / equity0×0.0×

Current ratio31.3×+0.3×

Where this comes from

Reported directly by CG Oncology in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's proceeds from disposition of marketable securities and other investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is CG Oncology's proceeds from disposition of marketable securities and other investments?: CG Oncology (CGON) reported proceeds from disposition of marketable securities and other investments of $252.85M in Q1 2026.
How has CG Oncology's proceeds from disposition of marketable securities and other investments changed year-over-year?: CG Oncology's proceeds from disposition of marketable securities and other investments increased by 26.3% year-over-year, from $200.14M to $252.85M.